MAIA Biotechnology, Inc.
New York Stock Exchange AmericanCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Vlad Vitoc
- Full Time Employees
- 13
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 444 West Lake Street Chicago IL United States of America 60606
- IPO Date
- Jul 28, 2022
- CIK
- 0001878313
- Website
- maiabiotech.com
- Similar Companies
- Business
- MAIA Biotechnology, Inc. (MAIA) develops and commercializes targeted immunotherapies for cancer, focusing on first-in-class drugs with novel mechanisms of action aimed at telomerase-positive cancer cells, particularly in non-small cell lung cancer (NSCLC). The company offers ateganosine (THIO or 6-thio-2'-deoxyguanosine), its lead investigational asset, a dual-mechanism telomere targeting agent that induces immunogenic cell death and enhances immunotherapy efficacy; THIO targets advanced NSCLC patients, often in combination with immune checkpoint inhibitors like cemiplimab (Libtayo); its pipeline advances through Phase 2 (THIO-101) and Phase 3 (THIO-104) trials for ICI-resistant NSCLC. MAIA Biotechnology operates in the oncology biotechnology sector, serving patients with advanced cancers through clinical-stage programs; it maintains headquarters in Chicago, Illinois, at 444 West Lake Street, Suite 1700; the company was founded in 2018. Recent developments include a $2.25 million private placement in September 2025 and a $736,600 private placement in October 2025 to fund clinical advancement; a $2.3 million grant award from the National Institutes of Health in September 2025 for the THIO-101 Phase 2 trial; positive Phase 2 THIO-101 data presented in 2025 showing 38% response rates, 17.8 months overall survival, and 30-month patient survival; trial updates at SITC 2025, IASLC World Conference, and AACR-NCI-EORTC; open market share purchases by CEO Vlad Vitoc and directors in November 2025 signaling confidence; and plans to initiate a digital asset treasury strategy in October 2025 focused on top-tier crypto assets.
MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial
MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial
MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer
MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University
MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial
MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial
MAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial
MAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial
MAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial Expansion
MAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial Expansion
MAIA Biotechnology Announces Open Market Purchases by CEO and Director
MAIA Biotechnology Announces Open Market Purchases by CEO and Director
MAIA Biotechnology Presents Trial in Progress Poster for Pivotal Phase 3 Clinical Trial of Novel Telomere Targeting Agent at 2026 Annual Meeting of American Society of Clinical Oncology
Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA)
MAIA Biotechnology Activates First U.S. Site for Ongoing International Phase 2 Expansion Trial of Novel Telomere Targeting Treatment Targeting Advanced Non-Small Cell Lung Cancer
MAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Anticancer Therapy
MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer
Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA)
Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA)
MAIA: Morgan Stanley to Cut 3% of Workforce Amid Shifting Business Priorities